首页> 美国卫生研究院文献>Springer Open Choice >Allosteric Inhibition of Serotonin 5-HT7 Receptors by Zinc Ions
【2h】

Allosteric Inhibition of Serotonin 5-HT7 Receptors by Zinc Ions

机译:锌离子对5-羟色胺5-HT7受体的变构抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The allosteric regulation of G protein-coupled receptors (GPCRs) is a well-known phenomenon, but there are only a few examples of allosteric modulation within the metabotropic serotonergic receptor family. Recently, we described zinc non-competitive interactions toward agonist binding at serotonin 5-HT1A receptors, in which biphasic effects, involving potentiation at sub-micromolar concentrations (10 μM) and inhibition at sub-millimolar concentrations (500 μM) of Zn2+ in radioligand binding assays, were consistent with both the agonist and antagonist-like effects of zinc ions observed in in vivo studies. Here, we showed new data demonstrating zinc allosteric inhibition of both agonist and antagonist binding at human recombinant 5-HT7 receptors stably expressed in HEK293 cells as observed by radioligand binding studies as well as zinc neutral antagonism displayed by the concentration of 10 μM in the functional LANCE assay. The allosteric nature of the effect of Zn on 5-HT7 receptors was confirmed (1) in saturation studies in which zinc inhibited the binding of potent orthosteric 5-HT7 receptor radioligands, the agonist [3H]5-CT, and the two antagonists [3H]SB-269970 and [3H]mesulergine, showing ceiling effect and differences in the magnitude of negative cooperativity (α = 0.15, 0.06, and 0.25, respectively); (2) in competition experiments in which 500 μM of zinc inhibited all radioligand displacements by non-labeled orthosteric ligands (5-CT, SB-269970, and clozapine), and the most significant reduction in affinity was observed for the 5-CT agonist (4.9–16.7-fold) compared with both antagonists (1.4–3.9-fold); and (3) in kinetic experiments in which 500 μM zinc increased the dissociation rate constants for [3H]5-CT and [3H]mesulergine but not for [3H]SB-269970. Additionally, in the functional LANCE test using the constitutively active HEK293 cell line expressing the 5-HT7 receptor, 10 μM zinc had features of neutral antagonism and increased the EC50 value of the 5-CT agonist by a factor of 3.2. Overall, these results showed that zinc can act as a negative allosteric inhibitor of 5-HT7 receptors. Given that the inhibiting effects of low concentrations of zinc in the functional assay represent the most likely direction of zinc activity under physiological conditions, among numerous zinc-regulated proteins, the 5-HT7 receptor can be considered a serotonergic target for zinc modulation in the CNS.
机译:G蛋白偶联受体(GPCR)的变构调节是一种众所周知的现象,但是在代谢型血清素能受体家族中仅有很少的变构调节实例。最近,我们描述了锌与5-羟色胺5-HT1A受体激动剂结合的非竞争性相互作用,其中双相效应涉及亚微摩尔浓度(10μM)时的增强作用和亚毫摩尔浓度(500μM)Zn 2 + 与体内研究中观察到的锌离子激动剂和拮抗剂样作用一致。在这里,我们显示了新的数据,证明了锌的变构抑制作用对HEK293细胞中稳定表达的人类重组5-HT7受体的激动剂和拮抗剂结合都具有抑制作用,这是通过放射性配体结合研究观察到的,并且通过功能中浓度为10μM的锌对中性拮抗作用LANCE分析。 (1)在饱和研究中证实了锌对5-HT7受体的变构性质,其中锌抑制了强效正构5-HT7受体放射性配体[ 3 H] 5的结合-CT以及两种拮抗剂[ 3 H] SB-269970和[ 3 H]美司他滨,表现出上限效应和负协同性大小的差异(α= 0.15) ,分别为0.06和0.25); (2)在竞争实验中,其中500μM的锌抑制了未标记的正构配体(5-CT,SB-269970和氯氮平)对所有放射性配体的位移,并且对5-CT激动剂的亲和力下降最明显(4.9–16.7倍)与两种拮抗剂(1.4–3.9倍)相比; (3)在动力学实验中,其中500μM的锌增加了[ 3 H] 5-CT和[ 3 H]甲磺胺碱的解离速率常数,但对于[< sup> 3 H] SB-269970。此外,在使用表达5-HT7受体的组成型活性HEK293细胞系进行的功能性LANCE测试中,10μM锌具有中性拮抗作用,并将5-CT激动剂的EC50值提高了3.2倍。总体而言,这些结果表明锌可以作为5-HT7受体的负变构抑制剂。鉴于功能测定中低浓度锌的抑制作用代表了生理条件下锌活性的最可能方向,在众多锌调节蛋白中,可以将5-HT7受体视为中枢神经系统中锌调节的血清素靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号